Assessing the introduction of universal human papillomavirus vaccination for preadolescent girls in The Netherlands

• Published in: Vaccine Vol. 25; no. 33; pp. 6245 - 6256
• Main Authors: Boot, Hein J, Wallenburg, Iris, de Melker, Hester E, Mangen, Marie-José M, Gerritsen, Annette A.M, van der Maas, Nicoline A, Berkhof, Johannes, Meijer, Chris J.L.M, Kimman, Tjeerd G
• Format: Journal Article
• Language: English
• Published: Oxford Elsevier Ltd 14.08.2007; Elsevier; Elsevier Limited
• Subjects: Age Distribution; Allergy and Immunology; Applied microbiology; Biological and medical sciences; Cervical cancer; Child; Coitus; Conflicts of interest; Contraindications; Cost-Benefit Analysis; Cost-effectiveness ratio; Drug Administration Schedule; Female; Fundamental and applied biological sciences. Psychology; Genotypes; HPV-vaccination; Human papillomavirus; Human papillomavirus 16; Humans; Immunization; Immunization Programs; Incidence; Medical sciences; Microbiology; Miscellaneous; National Immunization Program; Netherlands - epidemiology; Papillomavirus Infections - complications; Papillomavirus Infections - epidemiology; Papillomavirus Infections - prevention & control; Papillomavirus Vaccines - administration & dosage; Papillomavirus Vaccines - economics; Papillomavirus Vaccines - immunology; Quality of Life; Risk Factors; The Netherlands; Time Factors; Treatment Outcome; Tumors; Uterine Cervical Neoplasms - epidemiology; Uterine Cervical Neoplasms - prevention & control; Uterine Cervical Neoplasms - virology; Vaccines; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects); Virology; Womens health; Netherlands; Europe; United States > US; The Netherlands; HPV-vaccination; National Immunization Program; Cervical cancer; Cost-effectiveness ratio; Immunization; Vaccination; Vaccine; Papovaviridae; Malignant tumor; Female genital diseases; Papillomavirus; Virus; Human papillomavirus; Uterine cervix diseases; Cost efficiency analysis
• ISSN: 0264-410X; 1873-2518
• DOI: 10.1016/j.vaccine.2007.05.061

Abstract A persistent infection with human papillomavirus (HPV) is a prerequisite for the development of cervical cancer. Clinical trials with HPV-vaccines have been very successful in preventing persistent HPV16/18 infections, the two most oncogenic HPV-genotypes. We assessed the introduction of universal HPV-vaccination for preadolescent girls in the Dutch National Immunization Programme. Long-term vaccine efficacy, the need and extent of a catch-up programme for young women, and the impact of vaccination on the cervical cancer screening programme are major unresolved issues. Preliminary conservative estimates (80% vaccine efficacy and no effects on the screening programme, transmission rate, non-cervical cancer incidence, and cross protection) predict an acceptable cost-effectiveness ratio for universal vaccination of preadolescent girls.